These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33067866)

  • 1. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
    Thomas CD; Mosley SA; Kim S; Lingineni K; El Rouby N; Langaee TY; Gong Y; Wang D; Schmidt SO; Binkley PF; Estores DS; Feng K; Kim H; Kinjo M; Li Z; Fang L; Chapman AB; Cooper-DeHoff RM; Gums JG; Hamadeh IS; Zhao L; Schmidt S; Frye RF; Johnson JA; Cavallari LH
    CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):678-685. PubMed ID: 33067866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
    Parker RB; Soberman JE
    Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.
    Batty JA; Hall AS; White HL; Wikstrand J; de Boer RA; van Veldhuisen DJ; van der Harst P; Waagstein F; Hjalmarson Å; Kjekshus J; Balmforth AJ;
    Clin Pharmacol Ther; 2014 Mar; 95(3):321-30. PubMed ID: 24193112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.
    Qian J; Xu T; Pan P; Sun W; Hu G; Cai J
    Pharmacogenomics J; 2024 Apr; 24(3):13. PubMed ID: 38637522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction.
    Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1163-73. PubMed ID: 18648788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP 2D6*4 polymorphism and interindividual response variation to metoprolol in stage 1 hypertensive patients: no association in a rural Indian population?
    Ayyappadihas R; Dhanalekshmi U; Jestin H
    Turk J Med Sci; 2015; 45(2):352-7. PubMed ID: 26084127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.
    Nozawa T; Taguchi M; Tahara K; Hashimoto Y; Igarashi N; Nonomura M; Kato B; Igawa A; Inoue H
    J Cardiovasc Pharmacol; 2005 Nov; 46(5):713-20. PubMed ID: 16220080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics.
    Blake CM; Kharasch ED; Schwab M; Nagele P
    Clin Pharmacol Ther; 2013 Sep; 94(3):394-9. PubMed ID: 23665868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
    Damy T; Pousset F; Caplain H; Hulot JS; Lechat P
    Fundam Clin Pharmacol; 2004 Feb; 18(1):113-23. PubMed ID: 14748763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.
    Anstensrud AK; Molden E; Haug HJ; Qazi R; Muriq H; Fosshaug LE; Spigset O; Øie E
    Eur J Clin Pharmacol; 2020 May; 76(5):673-683. PubMed ID: 31940084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modelling to predict the pharmacokinetics of metoprolol in different CYP2D6 genotypes.
    Lee CM; Kang P; Cho CK; Park HJ; Lee YJ; Bae JW; Choi CI; Kim HS; Jang CG; Lee SY
    Arch Pharm Res; 2022 Jun; 45(6):433-445. PubMed ID: 35763157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.
    Koytchev R; Alken RG; Vlahov V; Kirkov V; Kaneva R; Thyroff-Friesinger U; Rehak E
    Eur J Clin Pharmacol; 1998 Aug; 54(6):469-74. PubMed ID: 9776437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
    Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
    Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the CYP2D6 genotype on the maintenance dose of metoprolol in a chronic Dutch patient population.
    Poulussen FCP; Peters BJ; Hua KH; Houthuizen P; Grouls RJ; Deenen MJ
    Pharmacogenet Genomics; 2019 Sep; 29(7):179-182. PubMed ID: 31107373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients.
    Taguchi M; Nozawa T; Kameyama T; Inoue H; Takesono C; Mizukami A; Hashimoto Y
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):385-8. PubMed ID: 12915955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of the effect of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of metoprolol
.
    Li S; Lin H; Sun W; Wang Y; Ding Y; Zhao H; Liu S
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):483-492. PubMed ID: 28139969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
    Hamadeh IS; Langaee TY; Dwivedi R; Garcia S; Burkley BM; Skaar TC; Chapman AB; Gums JG; Turner ST; Gong Y; Cooper-DeHoff RM; Johnson JA
    Clin Pharmacol Ther; 2014 Aug; 96(2):175-81. PubMed ID: 24637943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol.
    Yuan H; Huang Z; Yang G; Lv H; Sang H; Yao Y
    J Int Med Res; 2008; 36(6):1354-62. PubMed ID: 19094446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.